These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
790 related articles for article (PubMed ID: 28851427)
1. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
3. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study. Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076 [TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
8. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
11. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284 [TBL] [Abstract][Full Text] [Related]
12. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients. Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731 [TBL] [Abstract][Full Text] [Related]
14. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis. Kuwahara K; Ohba S; Nakae S; Hattori N; Pareira ES; Yamada S; Sasaki H; Abe M; Hasegawa M; Hirose Y Brain Tumor Pathol; 2019 Oct; 36(4):135-143. PubMed ID: 31324999 [TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060 [TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751 [TBL] [Abstract][Full Text] [Related]
17. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906 [TBL] [Abstract][Full Text] [Related]
18. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176 [TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas]. Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117 [No Abstract] [Full Text] [Related]
20. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]